Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.

Hasan Zia,Toyoaki Hida,S. Jakowlew,Michael J. Birrer,Yehoshua Gozes,J. Reubi,M. Fridkin,I. Gozes,T. W. Moody

Published 1996 in Cancer Research

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
1996
Venue
Cancer Research
Publication date
1996-08-01
Fields of study
Biology, Medicine
Identifiers
PMID 8758916
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
1995cited by this paper
Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.
1995cited by this paper
Multiple receptors for PACAP and VIP.
1994cited by this paper
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
1994cited by this paper
Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.
1993cited by this paper
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
1993cited by this paper
Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells
1993cited by this paper
Differential signal transduction by five splice variants of the PACAP receptor
1993cited by this paper
VIP analogues inhibit small cell lung cancer growth
1992cited by this paper
Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.
1992cited by this paper
Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research
1992cited by this paper
The VIP gene is expressed in non-small cell lung cancer cell lines
1992cited by this paper
A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.
1991cited by this paper
The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation.
1991cited by this paper
[Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo.
1991cited by this paper
An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
1991cited by this paper
4. The role of the epidermal growth factor receptor and the c‐erbB‐2 protein in breast cancer
1990cited by this paper
Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cyclic AMP levels.
1990cited by this paper
Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts
1990cited by this paper
Insulin-like growth factor receptor expression and function in human breast cancer.
1990cited by this paper
Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes.
1989cited by this paper
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
1989cited by this paper
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.
1989cited by this paper
Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
1988cited by this paper
Autoradiographic visualization of CNS receptors for vasoactive intestinal peptide.
1986cited by this paper
Vasoactive intestinal peptide and electrical activity influence neuronal survival.
1986cited by this paper
Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP-inducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity.
1984cited by this paper
Continuous culture and soft agarose cloning of multiple human breast carcinoma cell lines in serum-free medium.
1984cited by this paper
Comparison of VIP-secretin receptors in rat and human lung.
1981cited by this paper
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.
1979cited by this paper
A human cell line from a pleural effusion derived from a breast carcinoma.
1973cited by this paper
Polypeptide with Broad Biological Activity: Isolation from Small Intestine
1970cited by this paper

CITED BY

Non-DRE Voided Urine Test to Diagnose Prostate Cancer: Updated Results
2025cites this paper
VPAC receptor positivity in comparison with mp‐MRI in the diagnosis of prostate cancer: A preliminary study
2025cites this paper
The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy
2023cites this paper
Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice
2023cites this paper
Crosstalk of nervous and immune systems in pancreatic cancer
2023cites this paper
Diagnosis of Oral Cancers by Targeting VPAC Receptors: Preliminary Report
2023cites this paper
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
2022cites this paper
Diagnosis of cancer of the cervix by targeting VPAC receptors on exfoliated cervical cells
2022cites this paper
Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors
2022cites this paper
748 Targeting vasoactive intestinal peptide receptor signaling in pancreatic ductal adenocarcinoma for enhanced anti-tumor response to checkpoint blockade
2021cites this paper
Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin.
2021cites this paper
Obesity-related gut hormones and cancer: novel insight into the pathophysiology
2021cites this paper
Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors
2021cites this paper
Application of radiolabeled peptides in tumor imaging and therapy.
2020cites this paper
Radiolabeled peptides for SPECT and PET imaging in the detection of breast cancer: Preclinical and clinical perspectives.
2020cites this paper
Targeting VPAC1 Receptors for Imaging Glioblastoma
2019cites this paper
Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics
2019cites this paper
Adversarial generation of gene expression data
2019cites this paper
VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen
2018cites this paper
Development of a voided urine assay for detecting prostate cancer non‐invasively: a pilot study
2017cites this paper
Venom Peptides and Toxins - A Prospective Spearhead in Cancer Treatment.
2017cites this paper
Examination of PACAP During Lactation
2016cites this paper
Molecular imaging probes derived from natural peptides.
2016cites this paper
VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.
2016cites this paper
VPAC 1 targeted 64 Cu-TP 3805 PET imaging of prostate cancer : preliminary evaluation in man
2016cites this paper
VPAC2 receptor expression in human normal and neoplastic tissues: evaluation of the novel MAB SP235
2015cites this paper
Inhibition of Vasoactive Intestinal Polypeptide (VIP) Induces Resistance to Dextran Sodium Sulfate (DSS)-Induced Colitis in Mice
2014cites this paper
Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review).
2014cites this paper
VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study
2013cites this paper
VIP/PACAP Receptors
2013cites this paper
VPAC 1 Receptors for Imaging Breast Cancer : A Feasibility Study
2013cites this paper
Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1).
2012cites this paper
Changes in PACAP Immunoreactivity in Human Milk and Presence of PAC1 Receptor in Mammary Gland during Lactation
2012cites this paper
Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
2011cites this paper
Physical Activity and Natural Anti-VIP Antibodies: Potential Role in Breast and Prostate Cancer Therapy
2011cites this paper
Inflammatory breast cancer with refractory diarrhea: a case report.
2011cites this paper
Target-specific delivery of peptide-based probes for PET imaging.
2010cites this paper
Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.
2010cites this paper
Imaging Spontaneous MMTVneu Transgenic Murine Mammary Tumors: Targeting Metabolic Activity Versus Genetic Products
2010cites this paper
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
2009cites this paper
Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.
2008cites this paper
VIP, From Gene to Behavior and Back: Summarizing my 25 Years of Research
2008cites this paper
VPAC receptors as target for anti-cancer drug delivery
2008cites this paper
Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
2008cites this paper
Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker
2008cites this paper
Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.
2007cites this paper
Development of molecular and cellular biomarkers of pain.
2007cites this paper
Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
2007cites this paper
PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer
2007cites this paper
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.
2007cites this paper
Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.
2007cites this paper
Innervation of the canine mammary gland: an immunohistochemical study.
2007cites this paper
Vasoactive Intestinal Peptide Receptor Agonist : Functional Studies
2006cites this paper
Breast Cancer VPAC1 Receptors
2006cites this paper
VIP and PACAP as Autocrine Growth Factors in Breast and Lung Cancer
2006cites this paper
Breast Carcinoma Cell Lines Vasoactive Intestinal Polypeptide Receptor Type-1 in Human Retinoic Acid Down-Regulates the Expression of the Updated Version
2006cites this paper
PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.
2004cites this paper
VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
2004influential citation
The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells.
2004cites this paper
Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies
2004cites this paper
The development of VIP-ellipticine conjugates.
2004cites this paper
Neuropeptides as autocrine growth factors in cancer cells.
2003cites this paper
Expression of CRF1 and CRF2 receptors in human cancers.
2003cites this paper
VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens.
2003cites this paper
The Biological Significance of PACAP and PACAP Receptors in Human Tumors: From Cell Lines to Cancers
2003cites this paper
Peptide receptors as molecular targets for cancer diagnosis and therapy.
2003cites this paper
VIP as a trophic factor in the CNS and cancer cells.
2003cites this paper
In vitro and in vivo treatment of colon cancer by VIP antagonists.
2002cites this paper
Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR).
2002cites this paper
Nerve fibers in tumors of the human urinary bladder
2002cites this paper
Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity
2002cites this paper
VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
2002cites this paper
A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes.
2002cites this paper
Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts.
2002cites this paper
(N-stearyl, norleucine17) VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist
2002cites this paper
VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells
2001cites this paper
Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide
2001cites this paper
A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines
2001cites this paper
Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein*
2001cites this paper
Irradiation-induced effects on mast cells, neuropeptides, and atrial natriuretic peptide in the rat heart and lung: bases for further studies.
2001cites this paper
Estradiol down regulates expression of vasoactive intestinal polypeptide receptor type-1 in breast cancer cell lines.
2001cites this paper
Downregulation of VPAC1R Expression in Breast Cancer Cell Lines
2000cites this paper
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
2000cites this paper
Retinoic acid down-regulates VPAC1 receptors and TGF-β3 but up-regulates TGF-β2 in lung cancer cells
2000cites this paper
(Tyr(0),Bpa(4))bombesin is a GRP receptor agonist.
2000cites this paper
VIP‐derived sequences modified by N‐terminal stearyl moiety induce cell death: the human keratinocyte as a model
2000cites this paper
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
2000cites this paper
In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications
2000cites this paper
Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation
2000cites this paper
Retinoic acid down-regulates VPAC(1) receptors and TGF-beta 3 but up-regulates TGF-beta 2 in lung cancer cells.
2000cites this paper
Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours
2000cites this paper
Vasoactive Intestinal Peptide / Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin 1
2000cites this paper
Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.
1999cites this paper
Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro.
1999cites this paper
Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
1999cites this paper
Pharmaceutical VIP: prospects and problems.
1999cites this paper
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.
1999cites this paper
Vasoactive intestinal peptide (VIP) and VIP receptors: Gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood
1999cites this paper
Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.
1999cites this paper
PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells
1999cites this paper